LMLaurel H. Messer

Laurel H. Messer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laurel H. Messer has a total of 307 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cost‐Effectiveness of Control‐ IQ + Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States

    by Neda Al Rawashdh, Bimal V. Patel, Sharon M. Wang, Richard M. Zur, Pablo Anaya, Emily B. Kahn, Jordan E. Pinsker, Ravid Sasson‐Katchalski, Alex C. Trahan, Laurel H. Messer, et al.

    Objective: Automated insulin delivery (AID) has been established as an effective therapy for individuals with type 1 diabetes. This analysis evaluates the clinical and economic outcomes of AID compared with multiple daily injections plus continuous glucose monitoring (MDI/CGM) in adults with type 2 diabetes. Materials and Methods: The IQVIA CORE Diabetes Model v10.0 was employed to simulate the impact of using the t:slim X2 insulin pump with Control‐IQ+ technology (Control‐IQ+) versus MDI/CGM over a 50‐year period using data from the 2IQP randomized controlled trial (NCT05785832). Trial data informed cohort demographics, intervention effects and resource utilization while literature sources provided health state utilities and costs. Scenario analyses examined the effect of Control‐IQ+ on reducing HbA1c based on alternative HbA1c progression estimates from the Swedish National Diabetes Registry and alternative resource use and treatment effects from real‐world evidence. Results: The base case analysis indicated that direct medical costs per individual for type 2 diabetes management with Control‐IQ+ were $239 935 compared to $209 792 with MDI/CGM use. Control‐IQ+ resulted in 0.51 additional quality‐adjusted life years (QALYs: 10.36 vs. 9.85 for MDI/CGM), yielding an incremental cost‐effectiveness ratio (ICER) of $59 417 per QALY, 95% CI: ($55 836, $62 998). In probabilistic sensitivity analyses, 89% of simulations produced ICERs below $100 000/QALY. ICERs across all scenarios remained below $100 000 per QALY. Conclusions: Control‐IQ+ is associated with increased life expectancy, higher QALYs and reduced complication rates. These findings suggest that Control‐IQ+ is cost‐effective relative to MDI/CGM for managing patients with type 2 diabetes in the United States.

  • Open Access

    Rethinking control‐ IQ + technology: Simple strategies for easy optimization

    by Viral N. Shah, Pratik Choudhary, Ilana Halperin, Ivana Rabbone, Dessi P. Zaharieva, Laurel Messer

    Control‐IQ+ is an automated insulin delivery (AID) algorithm approved for people with type 1 diabetes aged 2+ years and adults aged 18+ years with type 2 diabetes. While numerous publications support improved glycaemia and quality of life for people with diabetes, this practice paper is intended to encourage uptake for healthcare professionals (HCPs) who are less familiar with AID systems. This includes recommendations for initializing settings, as well as research and practice‐based approaches to optimizing glycaemia with stronger settings (e.g., strong correction factor settings). In addition to automated insulin adjustments every 5 min, Control‐IQ+ delivers a large Autobolus up to once per hour, which can improve glycaemia in people who have challenges with routine bolusing. Simple bolus strategies and tips and tricks also highlight how to make Control‐IQ+ easy to use for HCPs and the person with diabetes.


  • Open Access

    Practical Considerations and Implementation of Automated Insulin Delivery Systems

    by Laurel H. Messer, Gregory P. Forlenza, Linda Gonder-Frederick, Korey Hood, Osagie Ebekozien, Katharine Barnard-Kelly, Lori M. Laffel, Jennifer L. Sherr, Rayhan Lal, Stuart A. Weinzimer

    The technological progress to date with automated insulin delivery (AID) has ushered in a new era of challenges and opportunities for people with diabetes (PWD), spotlighting implementation considerations. Beyond physiologic and technologic variation, cost, access, and health care professional (HCP) endorsement/experience lead to uneven uptake of AID technologies and attenuate universal ease of use. For AID to be broadly implemented, we must prioritize the lived experience for PWD and consider how to alleviate burden to promote physical/functional health, psychological well-being, and social well-being. Expectations and education help HCPs and PWD navigate the similarities and differences between AID devices, and help find common ties: users need to give the system time to work, learn to trust it, and not try to “trick” the system. Despite these learnings, disparities in uptake exist, both in clinical trials and in routine clinical care. Strategies to proactively address AID disparities must be enacted at multiple levels, including recognizing HCP biases, using clinic-based benchmarking efforts, and addressing insurance and policy barriers, all of which increase in importance as AID becomes more common for people with type 2 diabetes. Furthermore, broader implementation will require comprehensive health care system integration efforts, including new data solutions. Overall, the success of AID requires ongoing transformation of clinical paradigms, with lockstep alignment between PWD and their families, health care professionals, researchers, funders, policy makers, and industry partners.


  • Open Access

    Practical Considerations and Implementation of Automated Insulin Delivery Systems

    by Laurel H. Messer, Gregory P. Forlenza, Linda Gonder-Frederick, Korey Hood, Osagie Ebekozien, Katharine Barnard-Kelly, Lori M. Laffel, Jennifer L. Sherr, Rayhan Lal, Stuart A. Weinzimer

    Automated Insulin Delivery (AID) is in a new era of implementation challenges and opportunities for people with diabetes (PWD) and healthcare providers (HCPs). Beyond technologic variation, cost, access, and HCP endorsement/experience lead to uneven uptake of AID technologies, and attenuate universal ease of use. For AID to be broadly implemented, we must prioritize the lived experience for PWD, and consider how to alleviate burden to promote holistic wellbeing. Expectations and education help HCPs and PWD navigate the similarities and differences between AID devices, and help find common ties: users need to give the system time to work, learn to trust it, and not try to “trick” the system. Despite these learnings, disparities in uptake exist, both in clinical trials and in routine clinical care. Strategies to proactively address AID disparities are needed at multiple levels, all of which increase in importance as AID becomes more common for people with type 2 diabetes. Further, broader implementation will require comprehensive healthcare system integration efforts, including new data solutions. Overall, the success of AID requires ongoing transformation of clinical paradigms, with lockstep alignment between PWD and their families, healthcare professionals, researchers, funders, policy makers, and industry partners.


  • Open Access

    Control-IQ Technology Provides Similar Glycemic Outcomes Across Two Different CGM Sensors

    by Halis Kaan Akturk, Andy K. Johnson, John B. Welsh, Laurel H. Messer

    The t:slim X2 insulin pump with Control-IQ technology (Tandem Diabetes Care) is interoperable with G6 and, more recently, G7 sensors (Dexcom). CGM-derived metrics from customers who transitioned from using Control-IQ technology with G6 and then G7 sensors were compared. Median times in various glucose concentration ranges for the final 30 days of G6 use and the initial 30 days of G7 use changed by 70% and TBR (<70 mg/dL) <4%. Differences in sensor use, time in closed loop, and median glucose levels were clinically insignificant. Control-IQ-based pump users experienced similar outcomes and achieved excellent glycemic control with G6 or G7 sensors.


  • Glycemic and Patient-Reported Outcomes for Users of a New, Compact Automated Insulin Delivery System: A First Report

    by Halis K. Akturk, Kagan E. Karakus, Edwin D’souza, Kimia Z. Assadi, Jordan E. Pinsker, Laurel H. Messer


  • Open Access

    Understanding patient and health care provider perceptions of barriers and facilitators to diabetes care in immigrant and refugee populations

    by Michael E. Healy, Laurel H. Messer, Marilyn G. Stasinopoulos, Sarah E. Brewer, Arthur Berg, Tamara K. Oser


  • Open Access

    Towards the standardisation of adult person‐reported outcome domains in diabetes research: A Consensus Statement development panel

    by Katharine Barnard‐Kelly, David Marrero, Maartje de Wit, Frans Pouwer, Kamlesh Khunti, Norbert Hermans, Jessica S. Pierce, Lori Laffel, Richard I. G. Holt, Tadej Battelino, et al.

    Diabetes is unique among chronic diseases because clinical outcomes are intimately tied to how the person living with diabetes reacts to and implements treatment recommendations. It is further characterised by widespread social stigma, judgement and paternalism. This physical, social and psychological burden collectively influences self‐management behaviours. It is widely recognised that the individual's perspective about the impact of trying to manage the disease and the burden that self‐management confers must be addressed to achieve optimal health outcomes. Standardised, rigorous assessment of mental and behavioural health status, in interaction with physical health outcomes is crucial to aid understanding of person‐reported outcomes (PROs). Whilst tempting to conceptualise PROs as an issue of perceived quality of life (QoL), in fact health‐related QoL is multi‐dimensional and covers indicators of physical or functional health status, psychological and social well‐being. This complexity is illuminated by the large number of person reported outcome measures (PROMs) that have been developed across multiple psychosocial domains. Often measures are used inappropriately or because they have been used in the scientific literature rather than based on methodological or outcome assessment rigour. Given the broad nature of psychosocial functioning/mental health, it is important to broadly define PROs that are evaluated in the context of therapeutic interventions, real‐life and observational studies. This report summarises the central themes and lessons derived in the assessment and use of PROMs amongst adults with diabetes. Effective assessment of PROMs routinely in clinical research is crucial to understanding the true impact of any intervention. Selecting appropriate measures, relevant to the specific factors of PROs important in the research study will provide valuable data alongside physical health data.


  • Open Access

    “Obviously, Nothing's Gonna Happen in Five Minutes”: How Adolescents and Young Adults Infrastructure Resources to Learn Type 1 Diabetes Management

    by Tian Xu, Emily Jost, Laurel H. Messer, Paul F. Cook, Gregory P Forlenza, Sriram Sankaranarayanan, Casey Fiesler, Stephen Voida

    Learning personalized self-management routines is pivotal for people with type 1 diabetes (T1D), particularly early in diagnosis. Context-aware technologies, such as hybrid closed-loop (HCL) insulin pumps, are important tools for diabetes self-management. However, clinicians have observed that practices using these technologies involve significant individual differences. We conducted interviews with 20 adolescents and young adults who use HCL insulin pump systems for managing T1D, and we found that these individuals leverage both technological and non-technological means to maintain situational awareness about their condition. We discuss how these practices serve to infrastructure their self-management routines, including medical treatment, diet, and glucose measurement-monitoring routines. Our study provides insights into adolescents’ and young adults’ lived experiences of using HCL systems and related technology to manage diabetes, and contributes to a more nuanced understanding of how the HCI community can support the contextualized management of diabetes through technology design.